News | News By Subject | News by Disease News By Date | Search News

Idiopathic thrombocytopenic purpura (ITP) News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
GlaxoSmithKline (GSK) (Jobs) Release: Pivotal Phase III Trial Showed PROMACTA(R) (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP     6/11/2007
ALLIANT Pharmaceuticals, Inc. Signs Co-Promotion Agreement With Sanofi-Aventis (France) (SASY.PA) For Allegra(R) (fexofenadine hydrochloride) Oral Suspension     12/11/2006
GlaxoSmithKline (GSK) Release: Study Analysis Shows That Eltrombopag Significantly Improves Platelet Count And Response Rates In Idiopathic Thrombocytopenic Purpura (ITP)     6/19/2006

News from Around the Web
No News Posted on that date

Press Releases
Ligand (LGND) Release: Revolade Approved In EU As First In Class Therapy For Children Aged 1 Year And Above With Chronic ITP     4/7/2016
Ligand Pharmaceuticals Inc. (LGND) Initiates Phase II Trial with LGD-4665 in Idiopathic Thrombocytopenic Purpura     4/24/2008
SuppreMol Receives Orphan Drug Designation for SM101     9/12/2007
Protalex, Inc. (PRTX) Reports Clinical Progress of PRTX-100 in Rheumatoid Arthritis and Idiopathic Thrombocytopenic Purpura     6/28/2007
Data From Protalex, Inc. (PRTX)'s Phase I Clinical Trial Of PRTX-100 Presented At The American College Of Clinical Pharmacology     10/9/2006
GlaxoSmithKline (GSK) Announces Commencement Of Eltrombopag Phase III Worldwide Clinical Trial In Adults With Previously-Treated Idiopathic Thrombocytopenic Purpura     2/14/2006
Bayer Biological Products Release: Study Demonstrates Safety And Tolerability Of Higher Infusion Rate Using Gamunex(R), Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified     12/7/2004
Bayer Healthcare, Biological Products (NC) Release: Largest Randomized, Prospective Idiopathic [Immune] Thrombocytopenic Purpura (ITP) Study To Date Show Gamunex(R) Safe And Efficacious For Patients     6/1/2004